Norgine on a growth charge again with Theravia takeover deal
Netherlands-based pharma group Norgine has expanded its rare disease portfolio with the acquisition of France's Theravia for an undisclosed sum.
Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma
Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.
Ironwood crashes down as FDA seeks new phase 3 trial
Shares in Ironwood fell by a third after it revealed the FDA is insisting on a new phase 3 trial of its short bowel syndrome therapy apraglutide.
Failed trial knocks back wider use of BMS' Camzyos
Bristol-Myers Squibb's Camzyos has fallen short in a trial in non-obstructive hypertrophic cardiomyopathy, denting its growth prospects.
US starts the clock ticking on pharma tariffs
The US has launched a national security probe into the national security implications of importing pharmaceuticals, seen as a precursor to tariffs.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
The ESG in Life Sciences Summit is coming to the West Coast!
The ESG in Life Sciences Summit West is coming to San Francisco! (July 8-10, 2025).
World’s Largest Biopharma Forum for all mRNA Stakeholders
The mRNA field is on the cusp of revolutionary change, with cancer vaccines, in vivo cell engineering and gene editing technologies unleashing the next advancements of therapeutic candidat
Pharma Equipment Auction: Surepharm Assets Sale
Bid on used pharmaceutical production and packaging equipment. View auction April 22-24.
4th Liquid Biopsy for Precision Oncology East Coast
Better Identify Disease Risk, Detect Recurrence & Understand Treatment Responses with Ultra-Sensitive & Highly Accurate Liquid Biopsy Tests that Posit
PM Society announces the launch of The PMi Awards 2025
After 15 years as the PM Society Digital Awards, and after taking feedback from our membership, this successful event has evolved its name and sharpened its focus on impact and innovation.